CSF2 and neuroblastoma: Moreover, an ongoing phase II clinical trial (Clinical trial NCT04936529) is evaluating the protective efficacy of this bivalent vaccine (OBT-821) combined with β-glucan as a dietary supplement and granulocyte-macrophage colony-stimulating factor (GM-CSF), against NB.